New Delhi, Jun 28 (PTI) Drug firm Dr Reddy’s Laboratories today said it has received establishment inspection report (EIR) from the US health regulator for its two units at Medak district in Telangana. Also Read - Risk of Further Incitement of Violence: Twitter Permanently Suspends Trump's Account
In an earlier filing to the bourses on March 9, the drug firm had said it had received five observations from the US Food and Drug Administration (USFDA) for its API Hyderabad plant 3 at Medak district. Also Read - 9-Year-Old Telangana Boy Who Lost His Limbs in Accident Now Creates Art Using Mouth
On March 16, the company intimated the bourses that it had been issued a Form 483 with four observations for its API Hyderabad plant 1 at Jinnaram Mandal, Medak district. Also Read - US House Passes Bill to Provide Americans USD 2,000 Stimulus Checks, Sends it to GOP-led Senate
“…we have received an establishment inspection report (EIR) from the USFDA, for both of the above-referred facilities,” Dr Reddy’s said in a filing to BSE.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Shares of Dr Reddy’s Laboratories were today trading at Rs 2,300 per scrip on BSE, up 0.33 per cent from its previous close.
This is published unedited from the PTI feed.